6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy
Key Takeaways
Prostaglandin E1 (alprostadil) is a life-saving continuous infusion that maintains patency of the ductus arteriosus in neonates with ductal-dependent cyanotic, systemic, or parallel congenital heart disease.
PGE1 is initiated at 0.05-0.1 mcg/kg/min and titrated down to the lowest effective maintenance rate (0.01-0.025 mcg/kg/min) once ductal patency is established, minimizing adverse drug effects.
Apnea occurs in 10% to 20% of neonates receiving PGE1, most commonly within the first 60 minutes or at higher doses; transport crews must maintain a low threshold for elective prophylactic intubation prior to aeromedical or long-distance transport.
Exogenous surfactant (poractant alfa, beractant, calfactant) restores alveolar surface tension and functional residual capacity in preterm RDS and severe meconium aspiration syndrome.
Surfactant administration triggers a rapid, dramatic improvement in pulmonary compliance within minutes; transport clinicians must immediately wean peak inspiratory pressures (PIP) or tidal volume, reassess PEEP, and wean FiO2 to prevent alveolar overdistension, barotrauma, and tension pneumothorax.
Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy
Two pharmacological interventions stand out as uniquely transformative in neonatal critical care transport: Prostaglandin E1 (Alprostadil) and Exogenous Surfactant Replacement. Both therapies target life-threatening neonatal pathophysiologies that can rapidly deteriorate inside an aircraft or mobile intensive care unit. Mastery of ductal physiology, surfactant kinematics, administration techniques, and post-delivery ventilator adjustments is essential for high-scoring C-NPT candidates.
Prostaglandin E1 (Alprostadil): Ductal Architecture & Mechanism
In fetal circulation, the ductus arteriosus (DA) shunts oxygenated blood from the pulmonary artery directly into the descending aorta, bypassing high-resistance fetal pulmonary vasculature. Following birth, exposure to high ambient oxygen tensions and the abrupt withdrawal of maternal circulating prostaglandins trigger smooth muscle constriction, functional ductal closure within 12–24 hours, and anatomical obliteration within 2–3 weeks.
Alprostadil (PGE1) is a synthetic prostaglandin identical to endogenous . It binds to specific prostanoid EP receptors on ductal vascular smooth muscle, activating adenylyl cyclase, increasing intracellular cAMP, and driving calcium extrusion. This relaxes ductal smooth muscle, maintaining or re-establishing patency of the ductus arteriosus.
Clinical Classification of Ductal-Dependent Cardiac Lesions
Transport clinicians must identify when a neonate's survival depends entirely on maintaining a patent ductus arteriosus (PDA):
- Ductal-Dependent Pulmonary Blood Flow (Cyanotic Lesions): Pulmonary blood flow is obstructed; deoxygenated blood cannot reach the lungs without right-to-left or aorta-to-pulmonary shunting across the PDA. Examples: Pulmonary Atresia, Critical Pulmonary Stenosis, Tricuspid Atresia, severe Tetralogy of Fallot.
- Clinical Presentation: Severe, progressive central cyanosis unresponsive to 100% (hyperoxia test negative: mmHg).
- Ductal-Dependent Systemic Blood Flow (Acyanotic / Obstructive Lesions): Systemic blood flow is mechanically obstructed; the systemic circulation relies on right-to-left shunting from the pulmonary artery across the PDA into the descending aorta. Examples: Hypoplastic Left Heart Syndrome (HLHS), Critical Aortic Coarctation, Interrupted Aortic Arch, Critical Aortic Stenosis.
- Clinical Presentation: Gray, mottled skin, absent or diminished femoral pulses, differential blood pressures (>15–20 mmHg difference between upper and lower extremities), cardiogenic shock, severe metabolic acidosis, and anuria as the ductus constricts at 2–14 days of life.
- Parallel Circulations (Mixing Dependent): Systemic and pulmonary circulations run in parallel loops rather than series. Example: Transposition of the Great Arteries (TGA).
- Clinical Presentation: Profound cyanosis refractory to oxygen; survival requires bidirectional mixing at the atrial septum and PDA.
PGE1 Dosing, Titration & Administration Logistics
PGE1 has a very short half-life (5–10 minutes), with 70–80% cleared on first pass through the pulmonary vasculature. It requires a dedicated, continuous intravenous or intraosseous infusion.
- Initial Resuscitation Dose: 0.05 to 0.1 mcg/kg/min. In a neonate presenting in fulminant ductal closure and shock, this dose rapidly re-opens the constricted ductus, typically producing noticeable improvement in arterial oxygen saturation, pulses, and blood pressure within 15–30 minutes.
- Maintenance Titration: Once ductal patency and clinical stabilization are verified, the infusion rate must be titrated down to the lowest effective dose: 0.01 to 0.025 mcg/kg/min. Titrating downward minimizes systemic adverse effects during a prolonged transport.
- Infusion Mechanics: PGE1 can be infused through a peripheral IV, umbilical venous catheter (UVC), or intraosseous (IO) line. It should run via a dedicated lumen with microbore tubing. Inadvertent line flushing must be strictly prevented; a sudden bolus can trigger immediate apnea and cardiovascular collapse.
PGE1 Adverse Effects & Transport Airway Contingencies
| Adverse Effect | Approximate Incidence | Pathophysiological Mechanism | Transport Management Strategy |
|---|---|---|---|
| Apnea | 10% – 20% | Central depression of the medullary respiratory center; dose-dependent | Maintain low threshold for prophylactic elective intubation prior to transport departure. Have bag-mask resuscitator, suction, and appropriately sized ETT immediately available. |
| Hypotension & Flushing | 15% – 25% | Direct smooth muscle relaxation of systemic peripheral arterioles | Peripheral cutaneous erythema is benign. For systemic hypotension, administer a cautious isotonic crystalloid bolus (10 mL/kg normal saline) and wean PGE1 to maintenance. |
| Hyperthermia | 10% – 15% | Prostaglandin-mediated alteration of hypothalamic thermoregulatory set-point | High core temperatures (38.5–39.5°C) mimic sepsis. Differentiate from true infection; avoid overcooling; adjust isolette temperature down. |
| Seizure-Like Twitching | 1% – 3% | Cortical irritation / CNS excitation | Differentiate jitteriness from true electrographic seizure activity; reduce infusion rate if clinically tolerated. |
Deciding on Elective Intubation Before Transport
Apnea is the most hazardous complication of PGE1 during critical care transport. It occurs most frequently within the first 60 minutes of initiating therapy, especially at doses mcg/kg/min. In a cramped, vibrating aircraft cabin under night flying conditions, managing sudden neonatal apnea and unheralded bradycardia is exceptionally high-risk. Many programs strongly consider elective intubation before departure for infants on PGE1 who need air transport or a long ground transport, especially after a recent start or at higher doses. Observational studies show that many infants on low-dose PGE1 travel safely without intubation, so the decision weighs dose, apnea already observed, gestational age, and transport mode and duration. If intubation is withheld in a stable neonate on low maintenance dose (0.01 mcg/kg/min), the crew must maintain continuous capnography, pulse oximetry, and immediate airway equipment at the bedside.
Exogenous Surfactant Replacement Therapy
Pulmonary surfactant is an amphipathic complex of 90% lipids (primarily dipalmitoylphosphatidylcholine, DPPC) and 10% proteins (Surfactant Proteins A, B, C, and D) produced by type II alveolar pneumocytes. Surfactant reduces alveolar surface tension at low lung volumes, preventing end-expiratory alveolar collapse, stabilizing functional residual capacity (FRC), improving pulmonary compliance, and preventing non-cardiogenic pulmonary edema.
Transport Indications
- Neonatal Respiratory Distress Syndrome (RDS): Primary surfactant deficiency in preterm infants (<34–35 weeks gestation).
- Meconium Aspiration Syndrome (MAS): Secondary surfactant inactivation and chemical pneumonitis caused by free fatty acids, bile salts, and serum proteins.
- Neonatal Pneumonia & Sepsis: Inflammatory exudates inactivating alveolar surfactant.
Surfactant Preparations & Dosing
Modern surfactant preparations are derived from animal lung extracts containing essential hydrophobic proteins SP-B and SP-C:
- Poractant Alfa (Curosurf): Porcine lung extract. Highly concentrated, allowing smaller instillation volumes. Initial dose: 200 mg/kg (2.5 mL/kg) intratracheally. Subsequent doses: 100 mg/kg (1.25 mL/kg) every 12 hours if needed (max total 400 mg/kg).
- Beractant (Survanta): Modified bovine lung extract. Dose: 100 mg/kg (4.0 mL/kg) intratracheally in 4 divided aliquots, repeated every 6 hours (up to 4 doses in 48 hours).
- Calfactant (Infasurf): Calf lung extract. Dose: 105 mg/kg (3.0 mL/kg) intratracheally in 2 divided aliquots, repeated every 12 hours.
Administration Modalities: Traditional Catheter, INSURE & LISA
- Traditional Catheter Instillation via ETT: The infant is intubated. Surfactant is warmed to room temperature and instilled directly into the trachea using a catheter inserted through a multi-access suction port or inline adapter while maintaining mechanical ventilation.
- INSURE Method (INtubate - SURfactant - Extubate): The preterm neonate on non-invasive CPAP who develops worsening work of breathing is briefly intubated, receives surfactant, is gently ventilated for 5–15 minutes until stable, and is immediately extubated back to CPAP/NIPPV.
- LISA / MIST (Less Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy): Surfactant is administered to a spontaneously breathing infant maintained on CPAP via a thin vascular catheter or feeding tube threaded through the vocal cords under direct or video laryngoscopy, avoiding positive-pressure mechanical ventilation entirely.
- Transport Consideration: LISA and rapid INSURE require highly controlled environments. For long-distance interfacility transport, if the infant requires surfactant at the referring facility, standard practice often involves securing the ETT for the duration of transport to prevent accidental extubation and decompensation in transit.
Post-Administration Pulmonary Hemodynamics & Ventilator Weaning
The most dangerous phase of surfactant therapy occurs in the 5 to 30 minutes following successful delivery. As surfactant spreads across the alveolar-air interface, alveolar surface tension drops precipitously, producing an immediate, dramatic improvement in dynamic pulmonary compliance.
The Barotrauma & Volutrauma Trap
If the transport clinician leaves mechanical ventilator settings unchanged, the sudden rise in compliance will cause delivered tidal volumes to surge uncontrollably (volutrauma). High peak inspiratory pressures (PIP) acting on compliant lungs deliver excessive shear stress, rapidly causing:
- Pneumothorax and Pulmonary Interstitial Emphysema (PIE): Alveolar rupture into the pleural space.
- Acute Hypocarbia (–30 mmHg): Hyperventilation blows off carbon dioxide, causing profound cerebral vasoconstriction and predisposing the preterm infant to severe periventricular leukomalacia (PVL) and intraventricular hemorrhage (IVH).
Mandatory Action Post-Surfactant
Continuous bedside observation is mandatory immediately following instillation. As SpO2 rises and chest excursion increases, the clinician must rapidly wean PIP (or tidal volume), reassess PEEP, and titrate FiO2 downward to maintain target saturations and prevent air leak syndromes.
A transport respiratory therapist and nurse are transporting a 29-week preterm infant who received poractant alfa (Curosurf) at 200 mg/kg for severe respiratory distress syndrome 15 minutes prior to departure. During the initial ground transport phase, the mechanical ventilator alarms high tidal volume, chest rise is visibly excessive, and the transcutaneous monitor shows SpO2 rising to 100% while tcPCO2 drops rapidly from 48 mmHg to 24 mmHg. What acute physiological process has occurred, and what immediate ventilator adjustment must be performed?
The endotracheal tube has migrated into the right mainstem bronchus; immediately advance the tube another 1 cm and increase peak inspiratory pressure (PIP).
The infant has developed an acute tension pneumothorax; perform immediate needle thoracostomy at the second intercostal space midclavicular line.
Surfactant instillation has rapidly increased pulmonary compliance; immediately reduce peak inspiratory pressure (PIP) or tidal volume and decrease FiO2 to prevent barotrauma and hypocarbia-induced cerebral ischemia.
Surfactant has caused extensive atelectasis and airway plugging; increase PEEP from 5 to 10 cmH2O and perform deep tracheal suctioning.
A 2-day-old full-term infant with echocardiogram-confirmed critical coarctation of the aorta is being prepared for a 90-minute rotor-wing transport to a pediatric cardiac surgery center. The infant is currently breathing room air spontaneously with mild tachypnea and has just been started on a continuous infusion of Prostaglandin E1 (alprostadil) at 0.05 mcg/kg/min. Which adverse effect profile and operational airway decision should the transport crew prioritize before takeoff?
PGE1 causes severe bronchospasm in 50% of patients; administer nebulized albuterol every 15 minutes and avoid mechanical ventilation.
PGE1 causes pulmonary capillary leak and severe pulmonary hemorrhage; place a double-lumen endotracheal tube and initiate continuous positive airway pressure.
PGE1 causes hypercalcemic cardiac arrest; co-infuse intravenous furosemide and withhold intubation until absolute cardiac standstill occurs.
PGE1 causes apnea in 10% to 20% of neonates, usually within the first hour; strongly consider prophylactic elective intubation prior to rotor-wing flight due to the hazards of emergency in-flight airway management.
A 4-day-old infant presents in severe cardiogenic shock with gray skin, unpalpable femoral pulses, and severe metabolic acidosis. The transport physician suspects a closing ductus arteriosus in a ductal-dependent systemic obstructive lesion. The team initiates an alprostadil (PGE1) infusion. Once the ductus arteriosus opens—evidenced by palpable femoral pulses, narrowing blood pressure differential, and improving urine output—how should the PGE1 infusion be managed during the remaining 2 hours of transport?
Titrate the PGE1 infusion downward to the lowest effective maintenance rate (0.01 to 0.025 mcg/kg/min) to sustain ductal patency while minimizing hypotension, flushing, and hyperthermia.
Discontinue the PGE1 infusion immediately, because once the ductus reopens anatomically, smooth muscle tone cannot re-constrict for at least 72 hours.
Escalate the PGE1 infusion to 0.2 mcg/kg/min to ensure permanent pharmacological ablation of the ductal ligamentum arteriosum.
Switch the PGE1 infusion to an indomethacin infusion to stabilize the vascular endothelium against barometric pressure changes.
Sections you finish are checked off in the contents.